Unknown

Dataset Information

0

Efficacy of Sovodak in the Management of Patients Co-infected with HIV/HCV.


ABSTRACT: Purpose: Sofosbuvir (SOF) and daclatasvir (DOC) are suggested for the treatment of hepatitis C virus (HCV) in patients with concomitant HCV and human immunodeficiency virus (HIV). In 2016, Sovodak tablet a combination of SOF and DOC was introduced. In the present study we assessed the effectiveness of SOF in the treatment of HCV in patients co-infected with HIV. Methods: A total of 26 HCV patients co-infected with HIV received SOF for 3 months. One patient did not adhere to the drug protocol and was removed from the final analysis. The blood sample for qualitative polymerase chain reaction (PCR) was obtained after treatment and sustained virological response (SVR) was calculated. Results: Twenty five patients finished the study. The mean patients' age was 44.16±6.21 years. About 72% of participants had HCV genotype 1a, 8% genotype 1b, and 20% genotype 3a. After 3 months of intervention with Sovodak, the SVR12 was about 96%. None of the patients reported any adverse events. Conclusion: For the first time, the results of the present study showed that Sovodak had high SVR12 in HCV patients co-infected with HIV. However, for a precise conclusion, there is a need for larger studies and an equal number of patients with different virus genotypes.

SUBMITTER: Somi MH 

PROVIDER: S-EPMC7539312 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacy of Sovodak in the Management of Patients Co-infected with HIV/HCV.

Somi Mohammad Hossein MH   Sepehri Bita B   Sepehri Bita B   Nikniaz Zeinab Z   Sedghi Roya R  

Advanced pharmaceutical bulletin 20200809 4


<b><i>Purpose:</i></b> Sofosbuvir (SOF) and daclatasvir (DOC) are suggested for the treatment of hepatitis C virus (HCV) in patients with concomitant HCV and human immunodeficiency virus (HIV). In 2016, Sovodak tablet a combination of SOF and DOC was introduced. In the present study we assessed the effectiveness of SOF in the treatment of HCV in patients co-infected with HIV. <b><i>Methods:</i></b> A total of 26 HCV patients co-infected with HIV received SOF for 3 months. One patient did not adh  ...[more]

Similar Datasets

| S-EPMC4930150 | biostudies-literature
| S-EPMC3617231 | biostudies-literature
| S-EPMC3511493 | biostudies-literature
| S-EPMC4326686 | biostudies-literature
| S-EPMC5608492 | biostudies-literature
| S-EPMC6715635 | biostudies-literature
| S-EPMC5776657 | biostudies-literature
| S-EPMC7773414 | biostudies-literature
| S-EPMC4330991 | biostudies-literature
| S-EPMC9412373 | biostudies-literature